Observational studyMolecular biology reports2025
Evaluation of Apolipoprotein-A1 genetic polymorphisms as biomarkers for Chagas cardiomyopathy in patients from Córdoba, Argentina.
Observational study in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundChagas disease frequently leads to chronic chagasic cardiomyopathy, a major cause of mortality in endemic regions. Host genetic factors could potentially play a role in the progression of heart disease. This study aimed to assess the association between APOA1 polymorphisms and chagasic cardiomyopathy. METHODS AND
resultsA retrospective, observational study was conducted on 158 Trypanosoma cruzi-infected patients from Córdoba, Argentina, classified into three groups: G1 (without heart disease), G2 (with mild heart disease), and G3 (with severe heart disease). APOA1 G-75A and C+83T polymorphisms were genotyped using PCR-RFLP. No significant association was found between APOA1 polymorphisms and the overall presence or severity of chagasic cardiomyopathy (G1 vs. G2 + G3; G2 vs. G3). However, in subgroup analyses, the − 75/A allele was associated with an increased risk of ventricular extrasystoles (OR = 2.4; 95% CI: 1.04–5.53). Furthermore, sex- and age-stratified analyses revealed specific associations with arrhythmias for both the − 75/A and + 83/T variants. Notably, the heterozygous genotype for G-75A was associated with the progression of chagasic cardiac alterations in women (-75GA: OR = 4.35; 95% CI: 1.11–17.04).
conclusionAPOA1 genetic variants are not major determinants of chagasic cardiomyopathy at a population level in this cohort. However, our findings suggest they may act as modifiers of disease phenotype, modulating susceptibility to specific arrhythmic manifestations, particularly in demographic subgroups defined by sex and age. These results highlight the complex genetic architecture of Chagas disease and underline the need for further studies in larger cohorts to confirm these associations and elucidate their clinical relevance.
Indexed as
Identifiers
41324690What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.